CytrRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology and rare diseases. The Company is focused on the discovery, research and clinical development of anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The Company's Linker Activated Drug Release (LADR) technology platform is a discovery engine to create a pipeline of anti-cancer molecules that avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. Its product candidate, Aldoxorubicin is a rationally engineered cytotoxic which delivers anti-cancer agent, doxorubicin, into the tumor is in late-stage clinical trials. Its other product candidate, Arimoclomol is also in clinical trials for Niemann Pick disease Type C (NPC) and Gaucher disease through Orphazyme A/S.